Cargando…

Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

Influenza virus is a pathogen that causes morbidity and mortality worldwide. Whereas vaccination is important for prevention of disease, given its limitations, antiviral therapy is at the forefront of treatment and also plays a role in prevention. Currently, two classes of antiviral medications, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamali, Amanda, Holodniy, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838482/
https://www.ncbi.nlm.nih.gov/pubmed/24277988
http://dx.doi.org/10.2147/IDR.S36601
_version_ 1782478360573640704
author Kamali, Amanda
Holodniy, Mark
author_facet Kamali, Amanda
Holodniy, Mark
author_sort Kamali, Amanda
collection PubMed
description Influenza virus is a pathogen that causes morbidity and mortality worldwide. Whereas vaccination is important for prevention of disease, given its limitations, antiviral therapy is at the forefront of treatment and also plays a role in prevention. Currently, two classes of antiviral medications, the adamantanes and the neuraminidase inhibitors, are approved for treatment. Given the resistance patterns of circulating influenza, adamantanes are not recommended. Within the US, two neuraminidase inhibitors are currently approved for both treatment and prevention, while worldwide there are four available. In this review, we will briefly discuss the epidemiology and pathology of influenza and then discuss neuraminidase inhibitors: their mechanism of action, resistance, development, and future applications.
format Online
Article
Text
id pubmed-3838482
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38384822013-11-25 Influenza treatment and prophylaxis with neuraminidase inhibitors: a review Kamali, Amanda Holodniy, Mark Infect Drug Resist Review Influenza virus is a pathogen that causes morbidity and mortality worldwide. Whereas vaccination is important for prevention of disease, given its limitations, antiviral therapy is at the forefront of treatment and also plays a role in prevention. Currently, two classes of antiviral medications, the adamantanes and the neuraminidase inhibitors, are approved for treatment. Given the resistance patterns of circulating influenza, adamantanes are not recommended. Within the US, two neuraminidase inhibitors are currently approved for both treatment and prevention, while worldwide there are four available. In this review, we will briefly discuss the epidemiology and pathology of influenza and then discuss neuraminidase inhibitors: their mechanism of action, resistance, development, and future applications. Dove Medical Press 2013-11-19 /pmc/articles/PMC3838482/ /pubmed/24277988 http://dx.doi.org/10.2147/IDR.S36601 Text en © 2013 Kamali and Holodniy. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Kamali, Amanda
Holodniy, Mark
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
title Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
title_full Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
title_fullStr Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
title_full_unstemmed Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
title_short Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
title_sort influenza treatment and prophylaxis with neuraminidase inhibitors: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838482/
https://www.ncbi.nlm.nih.gov/pubmed/24277988
http://dx.doi.org/10.2147/IDR.S36601
work_keys_str_mv AT kamaliamanda influenzatreatmentandprophylaxiswithneuraminidaseinhibitorsareview
AT holodniymark influenzatreatmentandprophylaxiswithneuraminidaseinhibitorsareview